These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 17894706

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Evaluation of the therapeutic range of whole blood cyclosporin concentration in the treatment of psoriasis.
    Ieiri I, Nakayama J, Murakami H, Hori Y, Higuchi S.
    Int J Clin Pharmacol Ther; 1996 Mar; 34(3):106-11. PubMed ID: 8705088
    [Abstract] [Full Text] [Related]

  • 3. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
    Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB.
    J Am Acad Dermatol; 2007 Jan; 56(1):31.e1-15. PubMed ID: 17097378
    [Abstract] [Full Text] [Related]

  • 4. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
    Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L, Etanercept Psoriasis Study Group.
    Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
    [Abstract] [Full Text] [Related]

  • 5. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study.
    Ho VC, Griffiths CE, Berth-Jones J, Papp KA, Vanaclocha F, Dauden E, Beard A, Puvanarajan L, Paul C.
    J Am Acad Dermatol; 2001 Apr; 44(4):643-51. PubMed ID: 11260540
    [Abstract] [Full Text] [Related]

  • 6. A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis.
    Yoon HS, Youn JI.
    J Dermatolog Treat; 2007 Apr; 18(5):286-90. PubMed ID: 17852632
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
    Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, Stevens SR.
    J Am Acad Dermatol; 2007 Apr; 56(4):598-603. PubMed ID: 17113190
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cyclosporin in psoriasis: continuous monotherapy versus intermittent long-term therapy.
    Ozawa A, Sugai J, Ohkido M, Ohtsuki M, Nakagawa H, Kitahara H, Tamaki K, Urabe K, Nakayama J, Horikoshi T, Morimoto Y, Jimbow K.
    Eur J Dermatol; 1999 Apr; 9(3):218-23. PubMed ID: 10210789
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Intermittent cyclosporin A treatment of severe plaque psoriasis. Long-term follow-up of 26 patients.
    Peluso AM, Bardazzi F, Tosti A, Varotti C.
    Acta Derm Venereol Suppl (Stockh); 1994 Apr; 186():90-1. PubMed ID: 8073851
    [Abstract] [Full Text] [Related]

  • 14. Low-dose, short-term ciclosporin (Neoral®) therapy is effective in improving patients' quality of life as assessed by Skindex-16 and GHQ-28 in mild to severe psoriasis patients.
    Okubo Y, Natsume S, Usui K, Amaya M, Tsuboi R.
    J Dermatol; 2011 May; 38(5):465-72. PubMed ID: 21352289
    [Abstract] [Full Text] [Related]

  • 15. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J.
    Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial.
    Krueger GG, Elewski B, Papp K, Wang A, Zitnik R, Jahreis A.
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S112-9. PubMed ID: 16488321
    [Abstract] [Full Text] [Related]

  • 19. Clinical and immunohistochemical assessment of the effect of cyclosporin in keratinocytes and dermal dendrocytes in psoriasis.
    Lago E, Carneiro S, Cuzzi T, Magalhães G, Cássia F, Pessanha F, Ramos-e-Silva M.
    J Cutan Pathol; 2007 Jan; 34(1):15-21. PubMed ID: 17214849
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2).
    Reich K, Wozel G, Zheng H, van Hoogstraten HJ, Flint L, Barker J.
    Br J Dermatol; 2013 Jun; 168(6):1325-34. PubMed ID: 23621698
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.